K.J. Harrison & Partners Inc Has $5.35 Million Stake in Eli Lilly and Company (NYSE:LLY)

K.J. Harrison & Partners Inc cut its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 24.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,480 shares of the company's stock after selling 2,063 shares during the period. Eli Lilly and Company accounts for 1.0% of K.J. Harrison & Partners Inc's portfolio, making the stock its 23rd largest position. K.J. Harrison & Partners Inc's holdings in Eli Lilly and Company were worth $5,352,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in LLY. Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company during the 4th quarter valued at about $43,000. Prudent Man Investment Management Inc. bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $48,000. Highline Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 53.3% during the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after buying an additional 24 shares during the last quarter. Capital A Wealth Management LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $63,000. Finally, Bellwether Advisors LLC bought a new position in Eli Lilly and Company in the 4th quarter worth approximately $66,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 0.5%

NYSE LLY traded up $3.90 during trading on Monday, reaching $779.35. The company's stock had a trading volume of 3,040,079 shares, compared to its average volume of 3,681,016. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $738.62 billion, a PE ratio of 63.41, a PEG ratio of 1.13 and a beta of 0.41. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The business has a 50-day moving average price of $780.19 and a 200-day moving average price of $800.08.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.58 EPS. On average, research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. Eli Lilly and Company's payout ratio is currently 48.82%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on LLY. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. UBS Group reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.